CSIMarket
 
F star Therapeutics Inc   (FSTX)
Other Ticker:  
 
 
Price: $7.1200 $0.00 0.000%
Day's High: $7.12 Week Perf: 25.13 %
Day's Low: $ 7.11 30 Day Perf: 48.95 %
Volume (M): 987 52 Wk High: $ 0.00
Volume (M$): $ 7,027 52 Wk Avg: $0.00
Open: $7.11 52 Wk Low: $0.00



 Market Capitalization (Millions $) 156
 Shares Outstanding (Millions) 22
 Employees 56
 Revenues (TTM) (Millions $) 21
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 0

F Star Therapeutics Inc
F Star Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of cancer immunotherapy drugs. They specialize in developing novel bispecific antibodies, which are designed to target two different binding sites on cancer cells to activate the immune system to attack them. The company is headquartered in Cambridge, Massachusetts, USA, and has operations in the UK and the Netherlands.

The company was founded in 2006 by a team of biologists and biochemists, with a vision to create a new class of cancer therapeutics that harness the power of the immune system in fighting the disease. Their proprietary technology platform is built around the use of bispecific antibodies, which are engineered to bind to specific antigens on tumor cells, as well as activating immune cells, such as T-cells, to target and destroy them.

The company has a pipeline of over ten bispecific antibody candidates that are designed to target a range of cancers, including solid tumors, hematologic cancers, and rare cancers. Their lead product candidate, FS118, is a promising first-in-class bispecific antibody that targets both B7-H3 and CD3, two antigens that are commonly overexpressed on cancer cells. The drug is currently in Phase 1 clinical trials for the treatment of advanced solid tumors, and early results look promising.

F-Star is also working closely with other leading biotech companies and academic institutions, such as Merck KGaA and MD Anderson Cancer Center, to develop new candidate drugs that could be used in combination therapies for a range of cancers. Their research collaborations are focused on finding new ways to improve cancer immunotherapy, by developing new approaches to activate and recruit immune cells to the tumor microenvironment.

The company has a highly experienced and talented team of scientists and executives, who have a deep understanding of cancer biology and immunotherapy. They are highly committed to developing innovative new therapeutics that can make a difference in the lives of cancer patients around the world. With a strong pipeline and growing research collaborations, F-star Therapeutics looks poised to become a major player in the cancer immunotherapy space.


   Company Address: Eddeva B920 Babraham Research Campus Cambridge 0
   Company Phone Number: 1223-497400    Stock Exchange / Ticker: NASDAQ FSTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

F Star Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com